Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Research & Development (2021 - 2025)

Aligos Therapeutics' Research & Development history spans 5 years, with the latest figure at $17.0 million for Q4 2025.

  • For Q4 2025, Research & Development rose 6.28% year-over-year to $17.0 million; the TTM value through Dec 2025 reached $69.5 million, down 1.16%, while the annual FY2025 figure was $69.5 million, 1.16% down from the prior year.
  • Research & Development reached $17.0 million in Q4 2025 per ALGS's latest filing, down from $23.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $31.7 million in Q1 2022 to a low of $14.0 million in Q2 2025.
  • Average Research & Development over 5 years is $20.1 million, with a median of $18.0 million recorded in 2022.
  • Peak YoY movement for Research & Development: crashed 42.75% in 2023, then skyrocketed 42.7% in 2025.
  • A 5-year view of Research & Development shows it stood at $28.6 million in 2021, then tumbled by 33.21% to $19.1 million in 2022, then increased by 16.53% to $22.3 million in 2023, then dropped by 27.97% to $16.0 million in 2024, then rose by 6.28% to $17.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Research & Development are $17.0 million (Q4 2025), $23.9 million (Q3 2025), and $14.0 million (Q2 2025).